ClinicalTrials.gg
CompletedNCT01784068ENESTfreedomUpdated Aug 13, 2026Results posted

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

A Phase 2 interventional study of Nilotinib followed by treatment-free in Chronic Myelogenous Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 113 sites in 19 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
215
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
10th of 66
215 · median 55
Started
2013
with 10 others
Phase 2
25 of 66
1 open now
Registered
42nd of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 10th largest by enrollment, is one of 11 that started in 2013, is one of 25 in phase 2, and was the 42nd registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

The main purpose of the study was to investigate whether nilotinib treatment can be safely suspended with no recurrence of CML in selected patients who responded optimally on this treatment

Read the detailed description

The Primary objective of this study was to determine the percentage of patients who were in Major Molecular Response (MMR) at 48 weeks after starting the Treatment-Free Remission (TFR) phase (patients who required re-initiation of treatment were considered as non-responders).

Nilotinib treatment consolidation phase (NTCS): Patients who satisfied all inclusion/exclusion criteria were enrolled in the consolidation phase and continued to receive nilotinib for 52 weeks. All patients were treated with the planned nilotinib dose 300 mg BID (or at a reduced dose level of 400 mg QD if required from the perspective of toxicity). In order for patients to be eligible for the TFR phase, they had to fulfill the protocol specific definition of durable MRD. The four last quarterly performed PCR assessments must have fulfilled the following criteria:

  • The last assessment was MR4.5 (BCR-ABL ≤ 0.0032% IS)
  • No assessment worse than MR4.0 (BCR-ABL >0.01% IS) and
  • No more than two assessments between MR4.0 and MR4.5 (0.0032% IS\<BCR-ABL ≤ 0.01% IS)

Nilotinib Treatment-Free Remission (TFR) phase: Patients who were eligible to enter in the TFR phase after completing the 52 weeks consolidation phase, stopped taking nilotinib on the first day of the TFR phase. Duration of this phase was up to 10 years after the last patient enters in the TFR phase. BCR-ABL levels were monitored every four weeks during the first 48 weeks, every six weeks for the following 48 weeks and every 12 weeks during the last period.

Nilotinib treatment re-initiation (NTRI) phase: If a patient had a loss of MMR (BCR-ABL >0.1% IS) in the TFR phase, the patient restarted nilotinib treatment. Patients were on nilotinib treatment for up to 10 years after the last patient entered the nilotinib TFR phase. Patients who required re-initiation of nilotinib treatment were monitored for the BCR-ABL level every four weeks for the first 24 weeks and then every 12 weeks thereafter in patients who regained MMR. The frequency of BCR-ABL monitoring in patients not regaining MMR within the first 24 weeks after re-initiation of treatment was at least every 12 weeks or more frequently as clinically indicated.

03

Conditions studied

  • Chronic Myelogenous Leukemia

Keywords

  • AMN107
  • Ph+ CML-CP
  • chronic phase
  • nilotinib treatment
  • 2 years treatment
  • MR 4.5
  • Loss of MR 4
  • Loss of MMR
  • CML
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients ≥ 18 years of age
  • Minimum of 2 calendar years of nilotinib treatment with at least the last 12 months of nilotinib treatment prior to pre-screening at approved total daily dose of 600 mg BID or at a reduced dose of 400 mg QD if required from the perspective of tolerance for BCR-ABL positive CML in documented chronic phase at the time of diagnosis
  • Evidence of typical BCR-ABL transcripts (b3a2 and/or b2a2) at the time of CML-CP diagnosis i.e. prior to first start of TKI treatment which are amenable to standardized RT-PCR quantification"
  • Patient in MR4.5 at prescreening at Novartis designated lab
  • performance status of 0-2
  • Adequate end organ function as defined by:

    • Direct ≤ 1.5 x except for i) patients with documented Gilbert's syndrome for whom any bilirubin value is allowed and ii) for patients with asymptomatic hyperbilirubinemia (liver transaminases and alkaline phosphatase within normal range).
    • (AST) and SGPT(ALT) ≤ 3 x ULN i.e. equivalent to ≤ Grade 1 v.4.03
    • Serum lipase ≤ 2 x ULN i.e. equivalent to ≤ Grade 2 NCI-CTCAE v.4.03
    • Alkaline phosphatase ≤ 2.5 x ULN
    • Serum creatinine \< 1.5 x ULN
  • Patients must have the following electrolyte values within normal limits or corrected to be within normal limits with supplements prior to first dose of study medication:

    • Potassium (suggested keep to prevent issues with and/or rhythm abnormalities)
    • Magnesium (suggested keep to prevent issues with QT and/or rhythm abnormalities)
    • Total calcium (corrected for serum albumin)
  • Patients must have normal marrow function as defined:

    • (ANC) ≥ 1.5 x 10E9/L
    • ≥ 9.0 g/dL
    • ≥ 100 x 10E9/L
  • Documented chronic phase CML must meet all the criteria defined by:

    • \< 15% blasts in peripheral blood and bone marrow,
    • \< 30% blasts plus promyelocytes in peripheral blood and bone marrow,
    • \< 20% basophils in the peripheral blood,
    • ≥ 100 x 109/L (≥ 100,000/mm3) platelets,
    • No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly
  • Patients must tolerate a minimum total daily dose of nilotinib of 400 mg

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with BCR-ABL inhibitors other than nilotinib for more than a total cumulative duration of 4 weeks
  • Previous treatment with alpha-interferon of any duration
  • Previous anticancer agents for CML other than nilotinib except for cytoreduction after CML diagnosis until up to 4 weeks after first dose of nilotinib
  • Known second chronic phase of CML after previous progression to AP/BC
  • Poorly controlled diabetes mellitus (defined as > 9%)
  • Impaired cardiac function including any one of the following:

    • \< 45% or below the institutional lower limit of the normal range (whichever is higher)
    • Inability to determine the on , except for patients with evidence of measurable QT interval at the time of CML diagnosis (e.g. prior to first start of TKI treatment) and who have no documented clinical signs of cardiovascular disease and/or clinical signs of conduction abnormality.
    • Complete left bundle branch block
    • Right bundle branch block plus left anterior or posterior hemiblock
    • Use of a ventricular-paced pacemaker
    • Congenital long QT syndrome or a known family history of long QT syndrome
    • History of or presence of ventricular or atrial tachyarrhythmias
    • Clinically significant resting bradycardia
    • QTc > 450 msec on the average of three serial baseline ECG (using the QTcF formula). If QTcF > 450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-tested for QTc.This exclusion criterion is not applicable for patients with non-measurable QT interval who have evidence of measurable QT interval at the time of CML diagnosis (e.g. prior to first start of TKI treatment) and who have no documented clinical signs of cardiovascular disease and/or clinical signs of conduction abnormality.
    • History or clinical signs of myocardial infarction within 1 year of study entry
    • History of unstable angina within 1 year of study entry
    • Other clinically significant heart disease (e.g. congestive heart failure, cardiomyopathy or uncontrolled hypertension)
  • History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis
  • Known presence of significant congenital or acquired bleeding disorder unrelated to cancer
  • Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes, uncontrolled infection)
  • History of another active within 5 years prior to study entry with the exception of previous or concomitant basal cell skin cancer and previous carcinoma in situ treated curatively
  • Treatment with other agents (defined as not used in accordance with the approved indication) within 4 weeks of Day 1
  • Patients who have not recovered from prior surgery
  • Patients actively receiving therapy with strong inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug.
  • Patients actively receiving therapy with herbal medicines that are strong CYP3A4 inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. These herbal medicines may include Echinacea, (including E. purpurea, E. angustifolia and E. pallida), Piperine, Artemisinin, St. John's Wort, and Ginkgo.
  • Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either safely discontinued or switched to a different medication prior to starting study drug. (see http://www.torsades.org/medical-pros/drug-lists/printable-drug-list.cfm for a list of agents that prolong the QT interval)
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery)
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of during the study and for 14 days after the final dose of nilotinib. Highly effective contraception is defined as either:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
    • Male sterilization (at least 6 months prior to enrolling). For female patients on the study the vasectomized male partner should be the sole partner for that patient.
    • Use of a combination of any two of the following:

      1. Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception.
      2. Placement of an intrauterine device (IUD) or intrauterine system (IUS)
      3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.

In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment Women are considered and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to enrolling. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

If a study patient becomes pregnant or suspects being pregnant during the study or within 30 days after the final dose of nilotinib, the Study Doctor needs to be informed immediately and ongoing study treatment with nilotinib has to be stopped immediately.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
215 participants (actual)

Study arms

  • Experimental
    Nilotinib followed by treatment-free

    Patients who received a minimum of 2 years of first line nilotinib treatment and with pre-screen PCR results in ≥ MR4.5 entered the consolidation phase of the study (52 weeks - nilotinib 300 mg BID). Patients with Minimal Residual Disease (MRD) at the end of this phase entered the Treatment-Free Remission (TFR) phase where no treatment was given. Non eligible patients will enter the continuation phase of the study. Patients with MRD at the end of the continuation phase will enter the TFR-2 phase of the study where no treatment is given. Non eligible patients will enter the prolonged continuation phase of the study. If at any time during TFR or TFR-2 the patient loses MMR, nilotinib treatment will be immediately re-initiated (nilotinib 300 mg BID).

    Drug: Nilotinib followed by treatment-free

Interventions

  • DrugNilotinib followed by treatment-free

    Drug page: Nilotinib

    Nilotinib is being used as commercial available capsules (except in Japan where clinical supplies is used) of 150 mg and 200 mg strength. Treatment occurs during consolidation, continuation, prolonged continuation, re-initiation and re-initiation-2 phases of the study.

    Also known as: AMN107

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in Major Molecular Response at 48 Weeks After Start of Treatment-Free Remission (TFR) Phase

    The primary endpoint was the percentage of participants in major molecular response (MMR) at 48 weeks after initiation of the treatment-free remission (TFR) phase. Participants who required re-initiation of treatment were considered as non-responders.

    Time frame: 48 weeks in TFR

Secondary outcomes

  1. Percentage of Participants in MR4.5 (BCR-ABL ≤ 0.0032% IS) at 48 Weeks After Start of TFR Phase

    The outcome measure was the percentage of participants in molecular response 4.5 (MR4.5) at 48 weeks after initiation of the treatment-free remission (TFR) phase. Participants who required reinitiation of treatment were considered non-responders. MR4.5 corresponds to a BCR-ABL transcript level ≤0.0032% on the International Scale (IS), representing a deep molecular response.

    Time frame: 48 weeks in TFR

  2. Percentage of Participants in Major Molecular Response (MMR) at Multiple Time Points After Start of the Treatment-Free Remission (TFR) Phase

    This outcome measure was the percentage of participants in major molecular response (MMR) assessed at multiple timepoints after initiation of the treatment-free remission (TFR) phase. Participants who required re-initiation of treatment at any time prior to the respective assessment were considered non-responders.

    Time frame: Weeks 96, 144, 192, and 264, and End of Years 6, 7, 8, 9, and 10

  3. Percentage of Participants in Molecular Response 4.5 (MR4.5) at Multiple Time Points After Start of the Treatment-Free Remission (TFR) Phase

    This secondary outcome measure was the percentage of participants in molecular response 4.5 (MR4.5) assessed at multiple timepoints after initiation of the treatment-free remission (TFR) phase. Participants who required reinitiation of treatment at any time prior to the respective assessment were considered non-responders. MR4.5 corresponds to a BCR-ABL transcript level ≤0.0032% on the International Scale (IS).

    Time frame: Weeks 96, 144, 192, and 264, and End of Years 6, 7, 8, 9, and 10

  4. Number of Participants in Major Molecular Response (MMR) at Multiple Time Points After Start of the Treatment-Free Remission (TFR) Phase

    This outcome measure was the number of participants in major molecular response (MMR) assessed at multiple timepoints after initiation of the treatment-free remission (TFR) phase of nilotinib. At each assessment time point, participants with available MMR data were counted. Participants who reinitiated nilotinib treatment for less than 12 weeks prior to the respective assessment time point were excluded from the analysis at that time point.

    Time frame: Weeks 48, 96, 144, 192, and 264, and End of Years 6, 7, 8, 9, and 10

  5. Number of Participants in Molecular Response 4.5 (MR4.5) at Multiple Time Points After Start of the Treatment-Free Remission (TFR) Phase

    This outcome measure was the number of participants in molecular response 4.5 (MR4.5) assessed at multiple timepoints after initiation of the treatment-free remission (TFR) phase of nilotinib. At each assessment time point, participants with available MR4.5 data were counted. Participants who reinitiated nilotinib treatment for less than 12 weeks prior to the respective assessment time point were excluded from the analysis at that time point. MR4.5 corresponds to a BCR-ABL transcript level ≤0.0032% on the International Scale (IS).

    Time frame: Weeks 48, 96, 144, 192, and 264, and End of Years 6, 7, 8, 9, and 10

  6. Percentage of Participants Who Achieved Major Molecular Response (MMR) Within 12 Weeks of Reinitiation of Nilotinib Treatment

    Percentage of patients who achieved MMR within 12 weeks of re-initiation of treatment with nilotinib defined as the number of patients who were in MMR at least at 1 assessment within 12 weeks after re-start of nilotinib treatment divided by the number of patients who were re-initiated for at least 12 weeks.

    Time frame: 12 weeks after reinitiation of nilotinib treatment

  7. Percentage of Participants With Stable Major Molecular Response (MMR) at Multiple Time Points After First Achievement of MMR During Nilotinib Re-Initiation

    The percentage of patients who were in stable MMR after achieving a response in the NTRI phase at multiple timepoints was calculated by dividing the number of participants achieving MMR any time during the NTRI phase and having the same response at those timepoints after the first achievement of MMR, irrespective of whether there was loss of MMR in between, by the number of patients who achieved MMR at any time during the NTRI phase.

    Time frame: Weeks 48, 96, 144, 192, 240, 288, 336, 384, and 432 after first achievement of MMR during the nilotinib re-initiation phase

  8. Percentage of Participants With Stable Molecular Response 4.5 (MR4.5) at Multiple Time Points After First Achievement During Nilotinib Re-Initiation

    The proportion of patients who were in stable MR4.5 after achieving a response in the NTRI phase at multiple timepoints was calculated by dividing the number of participants achieving MR4.5 any time during the NTRI phase and having the same response at those timepoints after the first achievement of MR4.5, irrespective of whether there was loss of MR4.5 in between, by the number of patients who achieved MR4.5 at any time during the NTRI phase.

    Time frame: Weeks 48, 96, 144, 192, 240, 288, 336, 384, and 432 after first achievement of MR4.5 during the nilotinib re-initiation phase

  9. BCR-ABL Ratio (%) Over Time in Nilotinib Treatment Re-initiation Phase (NTRI)

    The BCR-ABL ratio (%) represents the level of BCR-ABL fusion gene transcripts relative to a control gene (ABL) measured in peripheral blood samples using quantitative reverse transcription polymerase chain reaction (RT-PCR). Results are expressed as a percentage on the International Scale (IS), a standardized reporting method that allows comparison across laboratories. The BCR-ABL ratio is used to assess the molecular response to treatment, with lower values indicating a reduced disease burden.

    Time frame: Baseline; every 4 weeks up to Week 24; and every 12 weeks thereafter, up to Week 528

  10. Duration of Re-Initiated Nilotinib Treatment Required to Regain Major Molecular Response (MMR) After Loss of MMR

    This outcome measure was defined as the time from the date of reinitiation of nilotinib treatment following loss of major molecular response (MMR) to the date of first documented achievement of MMR. Participants who did not regain MMR after reinitiation of treatment on or before the data cut-off date were censored at the date of their last available BCR-ABN PCR assessment.

    Time frame: Every 4 weeks up to Week 24, and every 12 weeks thereafter, up to Week 528

  11. Duration of Re-Initiated Nilotinib Treatment Required to Regain Molecular Response 4.5 (MR4.5) After Loss of MMR

    This outcome measure was defined as the time from the date of reinitiation of nilotinib treatment following loss of major molecular response (MMR) to the date of first documented achievement of molecular response 4.5 (MR4.5). Participants who did not regain MR4.5 after reinitiation of treatment on or before the data cut-off date were censored at the date of their last available BCR-ABN PCR assessment. MR4.5 corresponds to a BCR-ABN transcript level ≤0.0032% on the International Scale (IS).

    Time frame: From start of Nilotinib treatment re-initiation up to Week 528

  12. Treatment-Free Survival (TFS) After Start of the Treatment-Free Remission (TFR) Phase

    Treatment-free survival (TFS) was defined as the time from the start of the treatment-free remission (TFR) phase to the earliest occurrence of loss of major molecular response (MMR), reinitiation of treatment for any reason, progression to accelerated phase (AP) or blast crisis (BC), or death due to any cause. Participants without an event on or before the data cut-off date were censored at the date of their last available disease assessment (polymerase chain reaction, cytogenetic, hematologic, or extramedullary assessment).

    Time frame: From start of the treatment-free remission (TFR) phase up to Week 528

  13. Progression-Free Survival (PFS) After Start of the Treatment-Free Remission (TFR) Phase

    Progression-free survival (PFS) was defined as the time from the start of the treatment-free remission (TFR) phase to the earliest occurrence of disease progression to accelerated phase (AP) or blast crisis (BC), or death due to any cause. Participants without an event on or before the data cut-off date were censored at the date of their last available disease assessment (cytogenetic, hematologic, or extramedullary assessment) or last contact for participants in follow-up.

    Time frame: From start of the treatment-free remission (TFR) phase up to Week 528

  14. Overall Survival (OS) After Start of the Treatment-Free Remission (TFR) Phase

    Overall survival (OS) was defined as the time from the start of the treatment-free remission (TFR) phase to death due to any cause. Participants who were alive on or before the data cut-off date were censored at the date of their last assessment or last known alive date for participants in follow-up.

    Time frame: From start of the treatment-free remission (TFR) phase up to Week 528

  15. Percentage of Participants With Treatment-emergent Adverse Events During the Entire Study

    This outcome measure summarized the overall occurrence of adverse events related to nilotinib during the study. A study drug-related adverse event was defined as any adverse event assessed by the investigator as related to nilotinib and reported during the nilotinib treatment consolidation (NTCS) phase, the treatment-free remission (TFR) phase, or the nilotinib treatment re-initiation (NTRI) phase.

    Time frame: From first dose of nilotinib through up to approximately 11 years of study participation, including the NTCS, TFR, and NTRI phases

  16. Number of Participants With BCR-ABL1 Mutations Associated With Resistance to Nilotinib After Loss of Major Molecular Response

    This outcome measure was the number of participants who developed BCR-ABL1 mutations associated with resistance to nilotinib following loss of major molecular response (MMR) after suspension of nilotinib treatment. Mutations assessed included, but were not limited to, T315I, E255K, Y253H, F359V, F359C, and F359I. The endpoint was calculated as the number of participants with at least one detected BCR-ABL1 mutation divided by the number of participants who experienced loss of MMR after nilotinib suspension.

    Time frame: From loss of major molecular response after nilotinib suspension through up to 528 weeks of study participation

07

Results

Posted Jan 14, 2021

Participant flow

Recruitment for the study comprised a total of 215 participants, who were enrolled at 132 clinical sites distributed across 19 different countries..

Nilotinib Treatment Consolidation Phase
Participant flow — Nilotinib Treatment Consolidation Phase
MilestoneNilotinib Treatment and Treatment-Free Remission Cohort
Started215
Completed203
Not completed12
Withdrew: Adverse event5
Withdrew: Physician decision2
Withdrew: Patient/guardian decision3
Withdrew: Death2
Nilotinib Treatment-free Remission Phase
Participant flow — Nilotinib Treatment-free Remission Phase
MilestoneNilotinib Treatment and Treatment-Free Remission Cohort
Started190
Completed65
Not completed125
Withdrew: Patient/guardian decision18
Withdrew: Lack of efficacy98
Withdrew: Death2
Withdrew: Physician decision4
Withdrew: Lost to follow-up3

Outcome measures

PrimaryPercentage of Participants in Major Molecular Response at 48 Weeks After Start of Treatment-Free Remission (TFR) Phase

The primary endpoint was the percentage of participants in major molecular response (MMR) at 48 weeks after initiation of the treatment-free remission (TFR) phase. Participants who required re-initiation of treatment were considered as non-responders.

Time frame:
48 weeks in TFR
Reported as:
Number · percentage of participants
Percentage of Participants in Major Molecular Response at 48 Weeks After Start of Treatment-Free Remission (TFR) Phase
percentage of participantsTFR Phase
Percentage of Participants in Major Molecular Response at 48 Weeks After Start of Treatment-Free Remission (TFR) Phase51.6 (44.2 to 58.9)
SecondaryPercentage of Participants in MR4.5 (BCR-ABL ≤ 0.0032% IS) at 48 Weeks After Start of TFR Phase

The outcome measure was the percentage of participants in molecular response 4.5 (MR4.5) at 48 weeks after initiation of the treatment-free remission (TFR) phase. Participants who required reinitiation of treatment were considered non-responders. MR4.5 corresponds to a BCR-ABL transcript level ≤0.0032% on the International Scale (IS), representing a deep molecular response.

Time frame:
48 weeks in TFR
Reported as:
Number · percentage of participants
Percentage of Participants in MR4.5 (BCR-ABL ≤ 0.0032% IS) at 48 Weeks After Start of TFR Phase
percentage of participantsTFR Phase
Percentage of Participants in MR4.5 (BCR-ABL ≤ 0.0032% IS) at 48 Weeks After Start of TFR Phase47.4 (40.1 to 54.7)
SecondaryPercentage of Participants in Major Molecular Response (MMR) at Multiple Time Points After Start of the Treatment-Free Remission (TFR) Phase

This outcome measure was the percentage of participants in major molecular response (MMR) assessed at multiple timepoints after initiation of the treatment-free remission (TFR) phase. Participants who required re-initiation of treatment at any time prior to the respective assessment were considered non-responders.

Time frame:
Weeks 96, 144, 192, and 264, and End of Years 6, 7, 8, 9, and 10
Reported as:
Number · percentage of participants
Percentage of Participants in Major Molecular Response (MMR) at Multiple Time Points After Start of the Treatment-Free Remission (TFR) Phase
percentage of participantsTFR Phase
Week 96 response48.9 (41.6 to 56.3)
Week 144 response46.8 (39.6 to 54.2)
Week 192 response44.7 (37.5 to 52.1)
Week 264 response41.6 (34.5 to 48.9)
Week 312 (Year 6) response38.4 (31.5 to 45.7)
Week 360 (Year 7) response37.4 (30.5 to 44.7)
Week 408 (year 8) response35.3 (28.5 to 42.5)
Week 468 (year 9) response34.2 (27.5 to 41.4)
Week 528 (year 10) response26.8 (20.7 to 33.7)
SecondaryPercentage of Participants in Molecular Response 4.5 (MR4.5) at Multiple Time Points After Start of the Treatment-Free Remission (TFR) Phase

This secondary outcome measure was the percentage of participants in molecular response 4.5 (MR4.5) assessed at multiple timepoints after initiation of the treatment-free remission (TFR) phase. Participants who required reinitiation of treatment at any time prior to the respective assessment were considered non-responders. MR4.5 corresponds to a BCR-ABL transcript level ≤0.0032% on the International Scale (IS).

Time frame:
Weeks 96, 144, 192, and 264, and End of Years 6, 7, 8, 9, and 10
Reported as:
Number · percentage of participants
Percentage of Participants in Molecular Response 4.5 (MR4.5) at Multiple Time Points After Start of the Treatment-Free Remission (TFR) Phase
percentage of participantsTFR Phase
Week 96 response46.3 (39.1 to 53.7)
Week 144 response45.8 (38.6 to 53.2)
Week 192 response43.2 (36.0 to 50.5)
Week 264 response40.0 (33.0 to 47.3)
Week 312 (Year 6) response37.9 (31.0 to 45.2)
Week 360 (Year 7) response36.3 (29.5 to 43.6)
Week 408 (year 8) response35.3 (28.5 to 42.5)
Week 468 (year 9) response33.7 (27.0 to 40.9)
Week 528 (year 10) response25.3 (19.3 to 32.1)
SecondaryNumber of Participants in Major Molecular Response (MMR) at Multiple Time Points After Start of the Treatment-Free Remission (TFR) Phase

This outcome measure was the number of participants in major molecular response (MMR) assessed at multiple timepoints after initiation of the treatment-free remission (TFR) phase of nilotinib. At each assessment time point, participants with available MMR data were counted. Participants who reinitiated nilotinib treatment for less than 12 weeks prior to the respective assessment time point were excluded from the analysis at that time point.

Time frame:
Weeks 48, 96, 144, 192, and 264, and End of Years 6, 7, 8, 9, and 10
Reported as:
Count of participants · Participants
Number of Participants in Major Molecular Response (MMR) at Multiple Time Points After Start of the Treatment-Free Remission (TFR) Phase
ParticipantsTFR Phase
Week 48 response98
Week 96 response93
Week 144 response89
Week 192 response85
Week 264 response79
Week 312 (Year 6) response73
Week 360 (Year 7) response71
Week 408 (year 8) response67
Week 468 (year 9) response65
Week 528 (year 10) response51
SecondaryNumber of Participants in Molecular Response 4.5 (MR4.5) at Multiple Time Points After Start of the Treatment-Free Remission (TFR) Phase

This outcome measure was the number of participants in molecular response 4.5 (MR4.5) assessed at multiple timepoints after initiation of the treatment-free remission (TFR) phase of nilotinib. At each assessment time point, participants with available MR4.5 data were counted. Participants who reinitiated nilotinib treatment for less than 12 weeks prior to the respective assessment time point were excluded from the analysis at that time point. MR4.5 corresponds to a BCR-ABL transcript level ≤0.0032% on the International Scale (IS).

Time frame:
Weeks 48, 96, 144, 192, and 264, and End of Years 6, 7, 8, 9, and 10
Reported as:
Count of participants · Participants
Number of Participants in Molecular Response 4.5 (MR4.5) at Multiple Time Points After Start of the Treatment-Free Remission (TFR) Phase
ParticipantsTFR Phase
Week 48 response90
Week 96 response88
Week 144 response87
Week 192 response82
Week 264 response76
Week 312 (Year 6) response72
Week 360 (Year 7) response69
Week 408 (year 8) response67
Week 468 (year 9) response64
Week 528 (year 10) response48
SecondaryPercentage of Participants Who Achieved Major Molecular Response (MMR) Within 12 Weeks of Reinitiation of Nilotinib Treatment

Percentage of patients who achieved MMR within 12 weeks of re-initiation of treatment with nilotinib defined as the number of patients who were in MMR at least at 1 assessment within 12 weeks after re-start of nilotinib treatment divided by the number of patients who were re-initiated for at least 12 weeks.

Time frame:
12 weeks after reinitiation of nilotinib treatment
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Major Molecular Response (MMR) Within 12 Weeks of Reinitiation of Nilotinib Treatment
percentage of participantsNTRI Phase
Percentage of Participants Who Achieved Major Molecular Response (MMR) Within 12 Weeks of Reinitiation of Nilotinib Treatment95.4 (88.6 to 98.7)
SecondaryPercentage of Participants With Stable Major Molecular Response (MMR) at Multiple Time Points After First Achievement of MMR During Nilotinib Re-Initiation

The percentage of patients who were in stable MMR after achieving a response in the NTRI phase at multiple timepoints was calculated by dividing the number of participants achieving MMR any time during the NTRI phase and having the same response at those timepoints after the first achievement of MMR, irrespective of whether there was loss of MMR in between, by the number of patients who achieved MMR at any time during the NTRI phase.

Time frame:
Weeks 48, 96, 144, 192, 240, 288, 336, 384, and 432 after first achievement of MMR during the nilotinib re-initiation phase
Reported as:
Number · percentage of participants
Percentage of Participants With Stable Major Molecular Response (MMR) at Multiple Time Points After First Achievement of MMR During Nilotinib Re-Initiation
percentage of participantsNTRI Phase
Stable MMR for 48 weeks84.3 (75.0 to 91.1)
Stable MMR for 96 weeks78.7 (68.7 to 86.6)
Stable MMR for 144 weeks68.5 (57.8 to 78.0)
Stable MMR for 192 weeks60.7 (49.7 to 70.9)
Stable MMR for 240 weeks48.3 (37.6 to 59.2)
Stable MMR for 288 weeks42.7 (32.3 to 53.6)
Stable MMR for 336 weeks38.2 (28.1 to 49.1)
Stable MMR for 384 weeks34.8 (25.0 to 45.7)
Stable MMR for 432 weeks30.3 (21.0 to 41.0)
SecondaryPercentage of Participants With Stable Molecular Response 4.5 (MR4.5) at Multiple Time Points After First Achievement During Nilotinib Re-Initiation

The proportion of patients who were in stable MR4.5 after achieving a response in the NTRI phase at multiple timepoints was calculated by dividing the number of participants achieving MR4.5 any time during the NTRI phase and having the same response at those timepoints after the first achievement of MR4.5, irrespective of whether there was loss of MR4.5 in between, by the number of patients who achieved MR4.5 at any time during the NTRI phase.

Time frame:
Weeks 48, 96, 144, 192, 240, 288, 336, 384, and 432 after first achievement of MR4.5 during the nilotinib re-initiation phase
Reported as:
Number · percentage of participants
Percentage of Participants With Stable Molecular Response 4.5 (MR4.5) at Multiple Time Points After First Achievement During Nilotinib Re-Initiation
percentage of participantsNTRI Phase
Stable MR4.5 for 48 weeks86.9 (77.8 to 93.3)
Stable MR4.5 for 96 weeks76.2 (65.7 to 84.8)
Stable MR4.5 for 144 weeks71.4 (60.5 to 80.8)
Stable MR4.5 for 192 weeks63.1 (51.9 to 73.4)
Stable MR4.5 for 240 weeks48.8 (37.7 to 60.0)
Stable MR4.5 for 288 weeks42.9 (32.1 to 54.1)
Stable MR4.5 for 336 weeks39.3 (28.8 to 50.5)
Stable MR4.5 for 384 weeks35.7 (25.6 to 46.9)
Stable MR4.5 for 432 weeks31.0 (21.3 to 42.0)
SecondaryBCR-ABL Ratio (%) Over Time in Nilotinib Treatment Re-initiation Phase (NTRI)

The BCR-ABL ratio (%) represents the level of BCR-ABL fusion gene transcripts relative to a control gene (ABL) measured in peripheral blood samples using quantitative reverse transcription polymerase chain reaction (RT-PCR). Results are expressed as a percentage on the International Scale (IS), a standardized reporting method that allows comparison across laboratories. The BCR-ABL ratio is used to assess the molecular response to treatment, with lower values indicating a reduced disease burden.

Time frame:
Baseline; every 4 weeks up to Week 24; and every 12 weeks thereafter, up to Week 528
Reported as:
Mean · Percent
BCR-ABL Ratio (%) Over Time in Nilotinib Treatment Re-initiation Phase (NTRI)
PercentNTRI Phase
Baseline0.22697 ± 0.194306
Week 40.43848 ± 1.302378
Week 80.14038 ± 0.527741
Week 120.03205 ± 0.172524
Week 160.01044 ± 0.055724
Week 200.00476 ± 0.027446
Week 240.00291 ± 0.011041
Week 360.00209 ± 0.010182
Week 480.00149 ± 0.007022
Week 600.00120 ± 0.006373
Week 720.00098 ± 0.003366
Week 840.00120 ± 0.006416
Week 960.00169 ± 0.010148
Week 1080.00492 ± 0.032543
Week 1200.00073 ± 0.002945
Week 1320.00055 ± 0.002217
Week 1440.00068 ± 0.002429
Week 1560.00074 ± 0.003559
Week 1680.00071 ± 0.003267
Week 1800.00047 ± 0.001156
Week 1920.00262 ± 0.016285
Week 2040.01753 ± 0.126293
Week 2160.00683 ± 0.048460
Week 2280.00427 ± 0.029012
Week 2400.00315 ± 0.016585
Week 2520.00660 ± 0.029570
Week 2640.01436 ± 0.061134
Week 2760.01784 ± 0.081702
Week 2880.01616 ± 0.098699
Week 3000.01865 ± 0.113939
Week 3120.02516 ± 0.124114
Week 3240.01939 ± 0.113715
Week 3360.01348 ± 0.078374
Week 3480.00801 ± 0.045810
Week 3600.01015 ± 0.057496
Week 3720.00509 ± 0.028312
Week 3840.00206 ± 0.010247
Week 3960.00137 ± 0.006892
Week 4080.00158 ± 0.007350
Week 4200.00171 ± 0.008446
Week 4320.00102 ± 0.004642
Week 4440.00057 ± 0.002430
Week 4560.00084 ± 0.002877
Week 4680.00083 ± 0.003204
Week 4800.03371 ± 0.156501
Week 4920.00062 ± 0.002046
Week 5040.00044 ± 0.001246
Week 5160.00073 ± 0.001920
Week 5280.00000
SecondaryDuration of Re-Initiated Nilotinib Treatment Required to Regain Major Molecular Response (MMR) After Loss of MMR

This outcome measure was defined as the time from the date of reinitiation of nilotinib treatment following loss of major molecular response (MMR) to the date of first documented achievement of MMR. Participants who did not regain MMR after reinitiation of treatment on or before the data cut-off date were censored at the date of their last available BCR-ABN PCR assessment.

Time frame:
Every 4 weeks up to Week 24, and every 12 weeks thereafter, up to Week 528
Reported as:
Median · Weeks
Duration of Re-Initiated Nilotinib Treatment Required to Regain Major Molecular Response (MMR) After Loss of MMR
WeeksNTRI Phase
Duration of Re-Initiated Nilotinib Treatment Required to Regain Major Molecular Response (MMR) After Loss of MMR7.0 (5.0 to 8.0)
SecondaryDuration of Re-Initiated Nilotinib Treatment Required to Regain Molecular Response 4.5 (MR4.5) After Loss of MMR

This outcome measure was defined as the time from the date of reinitiation of nilotinib treatment following loss of major molecular response (MMR) to the date of first documented achievement of molecular response 4.5 (MR4.5). Participants who did not regain MR4.5 after reinitiation of treatment on or before the data cut-off date were censored at the date of their last available BCR-ABN PCR assessment. MR4.5 corresponds to a BCR-ABN transcript level ≤0.0032% on the International Scale (IS).

Time frame:
From start of Nilotinib treatment re-initiation up to Week 528
Reported as:
Median · Weeks
Duration of Re-Initiated Nilotinib Treatment Required to Regain Molecular Response 4.5 (MR4.5) After Loss of MMR
WeeksNTRI Phase
Duration of Re-Initiated Nilotinib Treatment Required to Regain Molecular Response 4.5 (MR4.5) After Loss of MMR12.9 (12.1 to 15.1)
SecondaryTreatment-Free Survival (TFS) After Start of the Treatment-Free Remission (TFR) Phase

Treatment-free survival (TFS) was defined as the time from the start of the treatment-free remission (TFR) phase to the earliest occurrence of loss of major molecular response (MMR), reinitiation of treatment for any reason, progression to accelerated phase (AP) or blast crisis (BC), or death due to any cause. Participants without an event on or before the data cut-off date were censored at the date of their last available disease assessment (polymerase chain reaction, cytogenetic, hematologic, or extramedullary assessment).

Time frame:
From start of the treatment-free remission (TFR) phase up to Week 528
Reported as:
Median · Weeks
Treatment-Free Survival (TFS) After Start of the Treatment-Free Remission (TFR) Phase
WeeksTFR Phase
Treatment-Free Survival (TFS) After Start of the Treatment-Free Remission (TFR) Phase120.1 (36.9 to NA)
SecondaryProgression-Free Survival (PFS) After Start of the Treatment-Free Remission (TFR) Phase

Progression-free survival (PFS) was defined as the time from the start of the treatment-free remission (TFR) phase to the earliest occurrence of disease progression to accelerated phase (AP) or blast crisis (BC), or death due to any cause. Participants without an event on or before the data cut-off date were censored at the date of their last available disease assessment (cytogenetic, hematologic, or extramedullary assessment) or last contact for participants in follow-up.

Time frame:
From start of the treatment-free remission (TFR) phase up to Week 528
Reported as:
Median · Weeks
Progression-Free Survival (PFS) After Start of the Treatment-Free Remission (TFR) Phase
WeeksTFR Phase
Progression-Free Survival (PFS) After Start of the Treatment-Free Remission (TFR) PhaseNA (NA to NA)
SecondaryOverall Survival (OS) After Start of the Treatment-Free Remission (TFR) Phase

Overall survival (OS) was defined as the time from the start of the treatment-free remission (TFR) phase to death due to any cause. Participants who were alive on or before the data cut-off date were censored at the date of their last assessment or last known alive date for participants in follow-up.

Time frame:
From start of the treatment-free remission (TFR) phase up to Week 528
Reported as:
Median · Weeks
Overall Survival (OS) After Start of the Treatment-Free Remission (TFR) Phase
WeeksTFR Phase
Overall Survival (OS) After Start of the Treatment-Free Remission (TFR) PhaseNA (NA to NA)
SecondaryPercentage of Participants With Treatment-emergent Adverse Events During the Entire Study

This outcome measure summarized the overall occurrence of adverse events related to nilotinib during the study. A study drug-related adverse event was defined as any adverse event assessed by the investigator as related to nilotinib and reported during the nilotinib treatment consolidation (NTCS) phase, the treatment-free remission (TFR) phase, or the nilotinib treatment re-initiation (NTRI) phase.

Time frame:
From first dose of nilotinib through up to approximately 11 years of study participation, including the NTCS, TFR, and NTRI phases
Reported as:
Count of participants · Participants
Percentage of Participants With Treatment-emergent Adverse Events During the Entire Study
ParticipantsNTCS PhaseTFR PhaseNTRI Phase
Percentage of Participants With Treatment-emergent Adverse Events During the Entire Study834070
SecondaryNumber of Participants With BCR-ABL1 Mutations Associated With Resistance to Nilotinib After Loss of Major Molecular Response

This outcome measure was the number of participants who developed BCR-ABL1 mutations associated with resistance to nilotinib following loss of major molecular response (MMR) after suspension of nilotinib treatment. Mutations assessed included, but were not limited to, T315I, E255K, Y253H, F359V, F359C, and F359I. The endpoint was calculated as the number of participants with at least one detected BCR-ABL1 mutation divided by the number of participants who experienced loss of MMR after nilotinib suspension.

Time frame:
From loss of major molecular response after nilotinib suspension through up to 528 weeks of study participation
Reported as:
Count of participants · Participants
Number of Participants With BCR-ABL1 Mutations Associated With Resistance to Nilotinib After Loss of Major Molecular Response
ParticipantsTFR Phase
Number of Participants With BCR-ABL1 Mutations Associated With Resistance to Nilotinib After Loss of Major Molecular Response1

Adverse events

Collected over From first dose of nilotinib through up to approximately 11 years of study participation, including the NTCS phase (up to 52 weeks), TFR phase (up to 528 weeks), and NTRI phases (up to 500 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NTCS2/215 (0.9%)20/215 (9.3%)159/215 (74%)
TFR Phase2/190 (1.1%)34/190 (17.9%)136/190 (71.6%)
NTRI5/91 (5.5%)40/91 (44%)86/91 (94.5%)
NTCT0/13 (0%)1/13 (7.7%)11/13 (84.6%)
TFR-20/10 (0%)1/10 (10%)7/10 (70%)
NTRI-20/5 (0%)3/5 (60%)5/5 (100%)
NTCT-P0/3 (0%)0/3 (0%)2/3 (66.7%)
All Patients9/215 (4.2%)84/215 (39.1%)205/215 (95.3%)
Most frequent serious events
Showing 10 of 198
Most frequent serious events
EventNTCSTFR PhaseNTRINTCTTFR-2NTRI-2NTCT-PAll Patients
Angina pectorisCardiac disorders0/2151/1901/910/130/101/50/33/215
Cardiac failureCardiac disorders0/2151/1900/910/130/101/50/32/215
Coronary artery diseaseCardiac disorders0/2150/1903/910/130/101/50/34/215
Coronary artery occlusionCardiac disorders0/2150/1900/910/130/101/50/31/215
Abdominal herniaGastrointestinal disorders0/2150/1900/910/130/101/50/31/215
SepsisInfections and infestations0/2150/1900/910/130/101/50/31/215
Urinary tract infectionInfections and infestations0/2150/1901/910/130/101/50/32/215
SeromaInjury, poisoning and procedural complications0/2150/1900/910/130/101/50/31/215
OsteoarthritisMusculoskeletal and connective tissue disorders0/2153/1900/910/130/101/50/34/215
Cerebral infarctionNervous system disorders0/2150/1900/910/130/101/50/31/215
Most frequent other events
Showing 10 of 171
Most frequent other events
EventNTCSTFR PhaseNTRINTCTTFR-2NTRI-2NTCT-PAll Patients
CoughRespiratory, thoracic and mediastinal disorders8/21512/1906/911/131/103/50/330/215
NasopharyngitisInfections and infestations22/21532/19019/910/130/102/50/358/215
SinusitisInfections and infestations3/2159/1904/910/131/102/50/317/215
ArthralgiaMusculoskeletal and connective tissue disorders24/21544/19014/911/133/102/50/373/215
Pain in extremityMusculoskeletal and connective tissue disorders7/21518/1903/910/130/102/50/330/215
HeadacheNervous system disorders10/21523/19011/911/131/102/50/342/215
Oral disorderGastrointestinal disorders0/2150/1900/910/130/100/51/31/215
COVID-19Infections and infestations0/21521/1907/910/131/101/51/331/215
FolliculitisInfections and infestations4/2150/1901/910/131/100/51/37/215
FuruncleInfections and infestations0/2151/1900/910/130/100/51/32/215

Baseline characteristics

Age, Continuous
Age, Continuous(years)NTCS Phase
Median54.0 (21 to 86)
Sex: Female, Male
Sex: Female, Male(Participants)NTCS Phase
Female102
Male113
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)NTCS Phase
Caucasian189
Asian20
Unknown3
Native American1
Other2
08

Study locations

113 sites
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Lakes Research
    Miami Lakes, Florida 33014, United States
  • H Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214-3728, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Memorial Sloan Kettering
    New York, New York 10017, United States
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
  • Cancer Centers of the Carolinas
    Greenville, South Carolina 29605, United States
  • Tennessee Oncology PLLC
    Chattanooga, Tennessee 37404, United States
  • Community Cancer Trials of Utah
    Ogden, Utah 84405, United States
  • Novartis Investigative Site
    Buenos Aires, C1114AAN, Argentina
  • Novartis Investigative Site
    Graz, 8036, Austria
  • Novartis Investigative Site
    Rankweil, A-6830, Austria
  • Novartis Investigative Site
    Salzburg, 5020, Austria
  • Novartis Investigative Site
    Vienna, 1140, Austria
  • Novartis Investigative Site
    Vienna, A-1130, Austria
  • Novartis Investigative Site
    Sint-Niklaas, Oost Vlaanderen 9100, Belgium
  • Novartis Investigative Site
    Kortrijk, West-Vlaanderen 8500, Belgium
  • Novartis Investigative Site
    Brussels, 1090, Belgium
  • Novartis Investigative Site
    Brussels, 1200, Belgium
  • Novartis Investigative Site
    Charleroi, 6000, Belgium
  • Novartis Investigative Site
    Ghent, 9000, Belgium
  • Novartis Investigative Site
    Liège, 4000, Belgium
  • Novartis Investigative Site
    Varna, 9000, Bulgaria
  • Novartis Investigative Site
    Bogota, Cundinamarca 111411, Colombia
  • Novartis Investigative Site
    Montería, 230004, Colombia
  • Novartis Investigative Site
    Aarhus N, 8200, Denmark
  • Novartis Investigative Site
    Bayonne, Bayonne Cedex 64109, France
  • Novartis Investigative Site
    Saint Priest Jarez, Pays de la Loire Region 42270, France
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Brest, 29609, France
  • Novartis Investigative Site
    Corbeil-Essonnes, 91100, France
  • Novartis Investigative Site
    Dunkirk, 59240, France
  • Novartis Investigative Site
    Grenoble, 38043, France
  • Novartis Investigative Site
    Nantes, 44093, France
  • Novartis Investigative Site
    Rouen, 76038, France
  • Novartis Investigative Site
    Strasbourg, 67000, France
  • Novartis Investigative Site
    Strasbourg, 67085, France
  • Novartis Investigative Site
    Toulouse, 31059, France
  • Novartis Investigative Site
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Novartis Investigative Site
    Mannheim, Baden-Wurttemberg 68305, Germany
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60590, Germany
  • Novartis Investigative Site
    Düsseldorf, North Rhine-Westphalia 40225, Germany
  • Novartis Investigative Site
    Leipzig, Saxony 04103, Germany
  • Novartis Investigative Site
    Lübeck, Schleswig-Holstein 23563, Germany
  • Novartis Investigative Site
    Jena, Thuringia 07740, Germany
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Bayreuth, 95445, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Bonn, 53105, Germany
  • Novartis Investigative Site
    Bottrop, 46236, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Düsseldorf, 40479, Germany
  • Novartis Investigative Site
    Goslar, 38642, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hamburg, 22417, Germany
  • Novartis Investigative Site
    Magdeburg, 39104, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Stuttgart, 70376, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Athens, 106 76, Greece
  • Novartis Investigative Site
    Athens, 115 27, Greece
  • Novartis Investigative Site
    Budapest, H-1083, Hungary
  • Novartis Investigative Site
    Szeged, 6725, Hungary
  • Novartis Investigative Site
    Dublin, D03 VX82, Ireland
  • Novartis Investigative Site
    Galway, 12074, Ireland
  • Novartis Investigative Site
    Ancona, AN 60126, Italy
  • Novartis Investigative Site
    Brescia, BS 25123, Italy
  • Novartis Investigative Site
    Cona, FE 44124, Italy
  • Novartis Investigative Site
    Florence, FI 50134, Italy
  • Novartis Investigative Site
    Genova, GE 16132, Italy
  • Novartis Investigative Site
    Nuoro, NU 08100, Italy
  • Novartis Investigative Site
    Perugia, PG 06129, Italy
  • Novartis Investigative Site
    Reggio Calabria, RC 89124, Italy
  • Novartis Investigative Site
    Roma, RM 00161, Italy
  • Novartis Investigative Site
    Orbassano, TO 10043, Italy
  • Novartis Investigative Site
    Terni, TR 05100, Italy
  • Novartis Investigative Site
    Naples, 80131, Italy
  • Novartis Investigative Site
    Novara, 28100, Italy
  • Novartis Investigative Site
    Kashiwa, Chiba 277-8567, Japan
  • Novartis Investigative Site
    Sapporo, Hokkaido 060-8648, Japan
  • Novartis Investigative Site
    Sagamihara, Kanagawa 252-0375, Japan
  • Novartis Investigative Site
    Kumamoto, Kumamoto 860-8556, Japan
  • Novartis Investigative Site
    Sakai, Osaka 590-0197, Japan
  • Novartis Investigative Site
    Suita, Osaka 565-0871, Japan
  • Novartis Investigative Site
    Saga, Saga-ken 849-8501, Japan
  • Novartis Investigative Site
    Kawagoe, Saitama 3508550, Japan
  • Novartis Investigative Site
    Shimotsuga Gun, Tochigi 3210293, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 1138519, Japan
  • Novartis Investigative Site
    Shinjuku Ku, Tokyo 160-0023, Japan
  • Novartis Investigative Site
    Akita, 0108543, Japan
  • Novartis Investigative Site
    Groningen, 9713 GZ, Netherlands
  • Novartis Investigative Site
    Gdansk, 80-952, Poland
  • Novartis Investigative Site
    Warsaw, 02-172, Poland
  • Novartis Investigative Site
    Terrassa, Catalonia 08221, Spain
  • Novartis Investigative Site
    Pamplona, Navarre 31008, Spain
  • Novartis Investigative Site
    Oviedo, Principality of Asturias 33011, Spain
  • Novartis Investigative Site
    San Cristóbal de La Laguna, Santa Cruz De Tenerife 38320, Spain
  • Novartis Investigative Site
    Barakaldo, Vizcaya 48903, Spain
  • Novartis Investigative Site
    Barcelona, 08041, Spain

Showing the first 100 of 113 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2013 to primary completion in May 2016, 38 months.

Results were first posted in Jan 2021, 4 years 7 months after primary completion.

Of 25 industry-sponsored phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 69. This study's 38 months is below that.

Counting every sponsor, half of 126 studies reached it within 73 months; a quarter within 43 and three quarters within 124.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2013
First posted
Feb 5, 2013
StartActual
Mar 19, 2013
Primary completionActual
May 31, 2016
CompletionActual
Jan 23, 2025
Results first posted
Jan 14, 2021
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01784068
Responsible party
Sponsor
First posted
Feb 5, 2013
Start date
Mar 19, 2013
Primary completion
May 31, 2016
Completion
Jan 23, 2025
Results posted
Jan 14, 2021
Last update
Aug 13, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion